{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:10:43Z","timestamp":1768972243011,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at \u0141 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to \u20ac3,956 or \u20ac1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at \u20ac2,183, and \u20ac4,786 with a PASI 100 response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1000776","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T06:56:16Z","timestamp":1674716176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain"],"prefix":"10.3389","volume":"11","author":[{"given":"Paulina","family":"Maravilla-Herrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Alfonso Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Balea Filgueiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Carrascosa Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Delgado S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Dolz Sinisterra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Garc\u00eda-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Herranz Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mart\u00ednez Olmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Morales de los R\u00edos Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Hidalgo-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","unstructured":"2016"},{"key":"B2","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.adengl.2014.04.016","article-title":"Prevalence of psoriasis in Spain in the age of biologics","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B6","article-title":"\u00bf\u2018C\u00f3mo se mide la gravedad de la psoriasis?","author":"Grupo","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1468-3083.2006.01659.x","article-title":"A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II)","volume":"20","author":"Carrascosa","year":"2006","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","article-title":"Clinical goals and barriers to effective psoriasis care","volume":"9","author":"Strober","year":"","journal-title":"Dermatol Ther Heidelb"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/03007995.2018.1457516","article-title":"Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis","volume":"34","author":"Armstrong","year":"2018","journal-title":"Curr Med Res Opin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1067\/mjd.2000.107501","article-title":"The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms","volume":"43","author":"Wahl","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/PROM.S81428","article-title":"systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values","volume":"6","author":"M\u00f8ller","year":"2015","journal-title":"Patient Relat Outcome Meas."},{"key":"B13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta","year":"2020","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-020-00428-1","article-title":"Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL)","volume":"10","author":"Lacour","year":"2020","journal-title":"Dermatol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s13555-020-00441-4","article-title":"Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of japanese patients with moderate-to-severe psoriasis treated with Ixekizumab (UNCOVER-J)","volume":"10","author":"Honma","year":"2020","journal-title":"Dermatol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jdv.14007","article-title":"Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"31","author":"Puig","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1111\/jdv.13307","article-title":"The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice","volume":"29","author":"Polistena","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"B18","unstructured":"Encuesta Nacional de Salud 2011\u20132012\n            InstitutoNacional de Estad\u00edstica\n          2012"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2016.1219359","article-title":"EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis","volume":"20","author":"Pickard","year":"2017","journal-title":"J Med Econ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.33393\/grhta.2020.2146","article-title":"Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study","volume":"7","author":"Carretero","year":"2020","journal-title":"Glob Reg Health Technol Assess."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/jdv.15094","article-title":"Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom","volume":"32","author":"Warren","year":"2018","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"B23","unstructured":"Sickness absence in the UK labour market\u2014Office for National Statistics2020"},{"key":"B24","unstructured":"VIII Informe Adecco sobre absentismo\n            Blasco de LunaFJ\n            Barcel\u00f3 LarranD\n            Bl\u00e1zquez AgudoEM\n            Checa Mart\u00ednJL\n            Cirujano Gonz\u00e1lezA\n            Pend\u00e1s PevidaE\n          2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/jdv.17000","article-title":"Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study","volume":"35","author":"Richard","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B26","unstructured":"Real Decreto 231\/2020, de 4 de febrero, por el que se fija el salario m\u00ednimo interprofesional para 20202020"},{"key":"B27","author":"Ortega","year":"2017","journal-title":"Gu\u00eda de Evaluaci\u00f3n Econ\u00f3mica e Impacto Presupuestario en los Informes de Evaluaci\u00f3n de Medicamentos."},{"key":"B28","unstructured":"Gasto total, gastos medios y distribuci\u00f3n del gasto de los hogares\n            InstitutoNacional de Estad\u00edstica\n          2020"},{"key":"B29","unstructured":"Encuesta Anual de Estructura Salarial 2016\n            InstitutoNacional de Estad\u00edstica\n          2016"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-020-00363-1","article-title":"Stigmatization and quality of life in patients with psoriasis","volume":"10","author":"Jankowiak","year":"2020","journal-title":"Dermatol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1046\/j.1365-2133.2003.05156.x","article-title":"Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?","volume":"148","author":"Schiffner","year":"2003","journal-title":"Br J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2012.50","article-title":"Willingness to pay in dermatology: assessment of the burden of skin diseases","volume":"132","author":"Seidler","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00403-019-01900-5","article-title":"Willingness to pay and quality of life in patients with pruritic skin disorders","volume":"311","author":"Stefanidou","year":"2019","journal-title":"Arch Dermatol Res."},{"key":"B35","first-page":"46","article-title":"Willingness-to-pay and time trade-off: the burden of disease in patients with benign hyperpigmentation","volume":"12","author":"Maymone","year":"2019","journal-title":"J Clin Aesthetic Dermatol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.547","author":"Graham","year":"2016","journal-title":"Estimation of Annual Indirect Costs Associated With Moderate-to-Severe Plaque Psoriasis in the United States"},{"key":"B37","first-page":"1","article-title":"Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis","volume":"33","author":"Lebwohl","year":"2021","journal-title":"J Dermatol Treat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"adv00678","DOI":"10.2340\/actadv.v102.583","article-title":"Unmet needs in the management of moderate-to-severe psoriasis in spain: a multidimensional evaluation","volume":"102","author":"Zozaya","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-017-0911-8","article-title":"The public health value of vaccines beyond efficacy: methods, measures and outcomes","volume":"15","author":"Wilder-Smith","year":"2017","journal-title":"BMC Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1377\/hlthaff.2015.1088","article-title":"The social value of vaccination programs: beyond cost-effectiveness","volume":"35","author":"Luyten","year":"2016","journal-title":"Health Aff Proj Hope."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/fhep-2019-0021","article-title":"The social value of improvement in activities of daily living among the advanced Parkinson's disease population","volume":"23","author":"Sullivan","year":"2020","journal-title":"Forum Health Econ Policy."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1000776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T06:56:26Z","timestamp":1674716186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1000776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2023.1000776"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1000776","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1000776"}}